LinusBio

LinusBio is a precision exposome medicine platform company based in New York, founded in 2021. It emerged from a collaboration with the Icahn School of Medicine at Mount Sinai, leveraging expertise from a leading exposome laboratory. The company focuses on developing environmental exposure biomarkers to enhance early diagnosis, patient monitoring, and drug development for complex health conditions.

LinusBio's technology platform uses hair samples to capture environmental exposures over time. It employs advanced robotics, laser systems, and mass spectrometry to analyze metabolic responses. The platform also features an AI-powered pipeline that identifies molecular signatures, bridging genomics and environmental factors to assess individual health risks. Key products include ClearStrand™ASD, a diagnostic aid for autism, and StrandDx™ASD, a molecular biomarker test for autism spectrum disorder. The company also supports drug development through its platform services, catering to pharmaceutical companies and academic researchers.